Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Norharmane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.96 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.96 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.96 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.96 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.96 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.96 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.96 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.96 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.96 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.96 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.96 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.96 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.96 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.96 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.96 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.96 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.96 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.96 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.96 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norharmane SCHEMBL8683826 | 1.00 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL8686167 | 1.00 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL6081960 | 0.98 | CHUK (0.92) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL25834 | 0.98 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL29370219 | 0.98 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL9486853 | 0.98 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Carbazole SCHEMBL18684843 | 0.98 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL11561251 | 0.96 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL21378153 | 0.96 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL29217000 | 0.96 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2026-02-19 | — | — | US | claimed |
| CN-116270626-A | Application of nor Ha Erman in preparation of antibacterial agent | 浙江工业大学 | 2023-06-23 | — | — | CN | claimed |
| EP-3792262-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2025-04-15 | — | — | US | disclosed |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230377764-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES | THE UNIVERSITY OF CHICAGO (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230241244-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | US | disclosed |
| CN-116270626-A | Application of nor Ha Erman in preparation of antibacterial agent | 浙江工业大学 | 2023-06-23 | — | — | CN | disclosed |
| US-11574747-B2 | Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies | THE UNIVERSITY OF CHICAGO (US) | 2023-02-07 | — | — | US | disclosed |
| US-11433143-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-06 | — | — | US | disclosed |
| EP-4045054-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | The Regents of the University of California (US) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | GABRA1 3080/4885GABRG2 3264/4885GABRB3 1775/4885 |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | GABRA1 4779/4885GABRG2 4362/4885GABRB3 4705/4885 |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | FN1, MATR3, COL14A1 | GABRA1 2593/4885GABRG2 3047/4885GABRB3 2732/4885 |
| US-11433143-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | GABRA1 4778/4885GABRG2 4474/4885GABRB3 4528/4885 |
| US-20230241244-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | IDO1, IDO2, BID | GABRA1 4778/4885GABRG2 4474/4885GABRB3 4528/4885 |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | GABRA1 3080/4885GABRG2 3264/4885GABRB3 1775/4885 |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | GABRA1 3080/4885GABRG2 3264/4885GABRB3 1775/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | GABRA1 3013/4885GABRG2 3329/4885GABRB3 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.